These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38541708)

  • 1. Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study).
    Ehsan H; Robinson M; Voorhees PM; Cassetta K; Borden S; Atrash S; Bhutani M; Varga C; Pineda-Roman M; Friend R; Paul BA
    Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
    Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
    Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
    Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
    Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
    Pasvolsky O; Ghanem S; Milton DR; Masood A; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2023 Dec; 29(12):757-762. PubMed ID: 37673125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
    Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
    BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
    Minarik J; Radocha J; Jungova A; Straub J; Jelinek T; Pika T; Pour L; Pavlicek P; Harvanova L; Pospisilova L; Krhovska P; Novakova D; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Maisnar V; Hajek R
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.
    Malandrakis P; Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
    Onco Targets Ther; 2020; 13():6405-6416. PubMed ID: 32669858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.
    Masood A; Iqbal Q; Ehsan H; Davis JA; Hansen DK; Hashmi H
    Ann Hematol; 2022 Dec; 101(12):2601-2610. PubMed ID: 36214853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
    Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA
    Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
    Nooka AK; Costa LJ; Gasparetto CJ; Richardson PG; Siegel DS; Chari A; Lentzsch S; Jagannath S; Mikhael J
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e526-e531. PubMed ID: 35361554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
    Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
    J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
    Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
    Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selinexor: Targeting a novel pathway in multiple myeloma.
    Mo CC; Yee AJ; Midha S; Hartley-Brown MA; Nadeem O; O'Donnell EK; Bianchi G; Sperling AS; Laubach JP; Richardson PG
    EJHaem; 2023 Aug; 4(3):792-810. PubMed ID: 37601856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
    Rocchi S; Tacchetti P; Pantani L; Mancuso K; Rizzello I; di Giovanni Bezzi C; Scalese M; Dozza L; Marzocchi G; Martello M; Barilà G; Antonioli E; Staderini M; Buda G; Petrini M; Cea M; Quaresima M; Furlan A; Bonalumi A; Cavo M; Zamagni E
    Hematol Oncol; 2021 Feb; 39(1):41-50. PubMed ID: 33085797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.
    Richard S; Jagannath S
    BioDrugs; 2022 Jan; 36(1):13-25. PubMed ID: 35113384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.
    Hari P; Mateos MV; Abonour R; Knop S; Bensinger W; Ludwig H; Song K; Hajek R; Moreau P; Siegel DS; Feng S; Obreja M; Aggarwal SK; Iskander K; Goldschmidt H
    Leukemia; 2017 Dec; 31(12):2630-2641. PubMed ID: 28439109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
    Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
    Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
    Markovic U; Romano A; Del Fabro V; Bellofiore C; Bulla A; Parisi MS; Leotta S; Gentile M; Cangialosi C; Vincelli I; Mineo G; Rossi M; Poidomani M; Uccello G; Maugeri C; Mannina D; Innao V; Di Raimondo F; Conticello C
    Front Oncol; 2021; 11():624405. PubMed ID: 33763359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India.
    Mehta P; Yadav N; Folbs B; Kapoor J; Khushoo V; Agrawal N; Ahmed R; Bhurani D
    Indian J Hematol Blood Transfus; 2022 Apr; 38(2):264-273. PubMed ID: 34248306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.